# EDGAR Filing Document

**Accession Number:** 0001728328
**File Stem:** 0001213900-25-063685
**Filing Date:** 2025-7
**Character Count:** 2039
**Document Hash:** 765b1528e3274401e8bef21e289d8185
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-063685.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0001213900-25-063685

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250714

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InMed Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001728328
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8
- **BUSINESS PHONE:** (604) 669-7207

**MAIL ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8

**INMED PHARMACEUTICALS INC.**<br> Suite 1445 – 885 West Georgia St.

Vancouver, British Columbia, Canada

V6C 3E8

**<u>VIA EDGAR</u>**

July 14, 2025

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

**Re: InMed Pharmaceuticals Inc.**

**Acceleration Request for Registration Statement on Form S-1**

**Filed July 9, 2025** 

**File No. 333-288594**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, InMed Pharmaceuticals Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to July 16, 2025, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable.

If you have any questions regarding this request, please contact Scott R. Saks of Norton Rose Fulbright US LLP at (212) 318-3151.

---

| |
|:---|
| Sincerely, |
| **INMED PHARMACEUTICALS INC.** |
| /s/ Eric A. Adams |
| Eric A. Adams |
| President and Chief Executive Officer |

---

cc: Netta Jagpal, *InMed Pharmaceuticals Inc.* <br> Scott R. Saks, *Norton Rose Fulbright US LLP* <br> Trevor Zeyl, *Norton Rose Fulbright Canada LLP*